Plaquenil Screening: How It Works, Results and What to Expect

Plaquenil screening is a set of painless eye tests used to look for early retinal changes linked to hydroxychloroquine (Plaquenil). Regular monitoring helps clinicians identify possible toxicity before it causes noticeable or permanent vision loss, while allowing many people to continue treatment safely.

Plaquenil Screening Overview

Plaquenil screening is eye monitoring for people who take hydroxychloroquine, a medicine commonly prescribed for lupus, rheumatoid arthritis, and some other inflammatory or autoimmune conditions. Although hydroxychloroquine is helpful for many people, long-term exposure can rarely affect the light-sensitive retinal tissue at the back of the eye. Screening is designed to find subtle changes early, often before a person notices a problem with vision.

The tests are usually comfortable, noninvasive, and completed in an ophthalmology or eye-care clinic. A screening visit commonly combines a discussion of medication use and health history with retinal imaging and a test that maps central vision. The results help the ophthalmologist and prescribing clinician decide whether routine monitoring can continue or whether more assessment is needed.

Retinal changes related to hydroxychloroquine may not improve after the medicine is stopped, particularly if they are found late. This is why scheduled screening matters even when vision seems normal. Screening does not mean that toxicity is expected; it is a precaution that supports safe, informed long-term treatment.

Who Needs Plaquenil Screening and When

Anyone taking hydroxychloroquine for an extended period should discuss retinal screening with the clinician who prescribes the medicine and an ophthalmologist. A baseline ophthalmic evaluation is generally recommended within the first year after starting treatment. It documents the retina and vision at the beginning of therapy and can identify eye conditions that may affect the choice or interpretation of later tests.

For many people at standard risk, annual screening begins after five years of continuous use. Earlier annual testing may be advised when a person has higher-risk features, including a daily dose above the recommended amount for their body weight, reduced kidney function, use of tamoxifen, pre-existing macular disease, or prolonged treatment. The care team may also individualize the schedule according to age, medical history, and prior test findings.

Hydroxychloroquine may be used to manage conditions such as lupus and inflammatory joint disease. Because stopping or changing treatment can lead to a flare of the underlying condition, decisions about medication should be made jointly by the ophthalmologist and the clinician managing the autoimmune disease.

How Plaquenil Screening Works: Tests Used

Plaquenil screening looks for a characteristic pattern of injury in the macula, the central part of the retina responsible for detailed vision. The ophthalmologist will usually check vision, review symptoms and medication history, and examine the eyes. Dilating eye drops may be used to provide a clearer view of the retina, although they are not required for every component of screening.

Optical coherence tomography (OCT) is a key imaging test. It uses reflected light to create highly detailed cross-sectional pictures of retinal layers. OCT can detect thinning or disruption in retinal areas that may be affected by hydroxychloroquine, sometimes before visible changes appear during a routine eye examination.

Automated visual field testing, often a 10-2 test for many patients, evaluates sensitivity in the central visual field. The patient presses a button when small lights are seen. People of Asian ancestry may have a pattern of retinal involvement farther from the center, so a wider field test, such as 24-2 or 30-2, may be selected. Fundus autofluorescence imaging and multifocal electroretinography may be used as additional or confirmatory tests when results are unclear.

• OCT: detailed retinal structure imaging.
• Visual field test: checks for small areas of reduced central vision.
• Fundus autofluorescence: shows patterns of retinal cell stress or damage.
• Multifocal electroretinography: measures electrical responses from different retinal areas when needed.

What Happens During the Procedure and Afterward

A Plaquenil screening appointment generally begins with a review of the medication dose, how long it has been taken, other medicines, kidney health, and any eye symptoms. Staff may measure visual acuity and eye pressure. If dilation is planned, eye drops are placed and typically take about 15 to 30 minutes to widen the pupils.

During OCT, the patient rests their chin and forehead on a support while looking at a target. The scanner captures images without touching the eye. During visual field testing, one eye is tested at a time while the patient looks ahead and responds whenever a light appears. Concentration is helpful, but the test can be repeated if blinking, fatigue, or unfamiliarity affects reliability.

Most people can return to usual activities right away. If dilating drops were used, blurred near vision and light sensitivity can last several hours. Sunglasses may improve comfort outdoors, and a person should avoid driving until vision is clear enough to do so safely. There is no physical recovery period after retinal imaging or visual field testing.

A normal result usually means there is no evidence of toxicity at that visit and that monitoring should continue at the recommended interval. An abnormal or uncertain result does not automatically confirm toxicity. The ophthalmologist may repeat a test, use another imaging method, compare current results with baseline images, or arrange closer follow-up before advising the prescribing clinician.

Benefits, Limits and Possible Risks of Screening

The main benefit of Plaquenil screening is early detection. When changes are recognized before central vision is affected, clinicians can reassess treatment promptly and help reduce the likelihood of progression to more significant retinal damage. Screening also provides reassurance when serial examinations remain stable.

The tests themselves are considered very low risk. OCT, visual field testing, fundus photography, and autofluorescence imaging do not involve radiation or injections. Temporary effects from dilation, such as glare and blurred close vision, are the most common practical inconvenience. Visual field testing can feel tiring or frustrating, especially at a first visit, because it depends on consistent responses.

No single test should be interpreted in isolation. Visual field results can be influenced by dry eye, cataracts, tiredness, learning effect, or difficulty maintaining focus. For this reason, suspected abnormalities are typically confirmed with an objective retinal imaging test before a treatment decision is made. The goal is to avoid both missed early disease and unnecessary interruption of an effective medication.

What Are the New Guidelines for Plaquenil Testing?

Current guidance from major ophthalmology organizations emphasizes a baseline eye examination soon after hydroxychloroquine is started and regular screening with sensitive tests before symptoms appear. Modern screening relies primarily on OCT plus automated visual field testing, with fundus autofluorescence or multifocal electroretinography used to clarify uncertain cases. The exact testing approach may be tailored to the individual and the pattern of risk.

Guidelines also emphasize safe prescribing according to actual body weight and close attention to duration of use. For people at standard risk, annual screening is generally recommended after five years of therapy. People with higher daily exposure, kidney disease, tamoxifen use, retinal disease, or other risk factors may need annual testing earlier.

Recommendations evolve as imaging technology and clinical evidence improve. Patients should follow the interval advised by their own ophthalmologist rather than relying only on a general calendar. Bringing an up-to-date medication list and, when possible, information about the daily dose and start date helps make screening more accurate.

How Common Is Retinal Toxicity With Plaquenil?

Retinal toxicity from hydroxychloroquine is uncommon when the medicine is prescribed at an appropriate dose and used for a relatively short time. Risk is strongly related to daily dose, duration of treatment, and individual health factors. The chance increases after many years of use, which is why long-term monitoring is especially important.

Higher risk has been associated with dose levels above recommended weight-based guidance, treatment beyond five years, reduced kidney function, concurrent tamoxifen treatment, and existing retinal or macular disease. These factors do not mean toxicity will occur, but they help clinicians decide when screening should start and how closely it should be repeated.

Most people who attend recommended follow-up appointments do not develop vision-threatening toxicity. If early changes are suspected, the care team can review the balance of benefits and risks of continued treatment. Prompt communication among the patient, ophthalmologist, and prescribing specialist is essential.

How Can You Tell Plaquenil Is Working? What Should Be Monitored?

Hydroxychloroquine is working when the condition it was prescribed to treat becomes better controlled. Depending on the diagnosis, this may mean fewer joint symptoms, less fatigue, fewer skin flares, improved rash control, or reduced disease activity on clinical assessment. Benefits can take weeks to months to become clear, and the prescribing clinician is best placed to judge response using symptoms, examination findings, and condition-specific laboratory tests.

Eye symptoms are not a reliable way to tell whether Plaquenil is effective, and retinal toxicity may begin without symptoms. People taking hydroxychloroquine should monitor for new difficulty reading, blurred or distorted central vision, color changes, missing spots, or trouble seeing in dim light, while recognizing that these symptoms can have many causes. New visual concerns should be reported promptly to an eye-care professional.

Monitoring usually includes the medication dose, body weight changes, kidney function when relevant, other medicines, and routine retinal screening. The clinician treating the underlying disease may also check blood counts, liver-related tests, or other markers based on the person’s diagnosis and overall health. Patients should not adjust the dose or stop treatment independently.

When to Seek Medical Care

People taking hydroxychloroquine should arrange routine eye screening as advised, even if they have no vision symptoms. They should contact an ophthalmologist or prescribing clinician sooner if they develop new blurred or distorted central vision, a dark or missing area in vision, unusual color perception, or persistent difficulty reading that is not explained by a simple change in glasses.

Sudden vision loss, a curtain-like shadow, severe eye pain, sudden flashes of light, or a sudden increase in floaters needs urgent medical assessment, as these symptoms can indicate eye problems unrelated to hydroxychloroquine that still require prompt care. In an emergency, local emergency services or an urgent eye-care service should be used.

For international patients, Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals can coordinate ophthalmic assessment alongside care for autoimmune and inflammatory conditions. A qualified clinician can explain the most appropriate screening plan based on medication exposure and personal risk factors.

Frequently asked questions

Does Plaquenil screening hurt?

No. The main screening tests, including OCT imaging and visual field testing, are noninvasive and should not be painful. If pupil-dilating drops are used, they may cause temporary stinging, light sensitivity, and blurred near vision.

How long does a Plaquenil eye screening appointment take?

The time varies by clinic and whether dilation is needed. Testing itself is often relatively brief, but a full visit may take longer because of check-in, examination, dilation, and review of results.

Do I need screening if I have no vision symptoms?

Yes. Early hydroxychloroquine-related retinal changes may occur without noticeable symptoms. Regular screening is intended to identify changes before they affect daily vision.

Can I drive after Plaquenil screening?

If the pupils are dilated, vision may be blurry and lights may seem brighter for several hours. It is safest to arrange transportation or wait to drive until vision has returned to normal.

What happens if a Plaquenil screening result is abnormal?

An abnormal result often needs confirmation because several conditions and testing factors can mimic retinal changes. The ophthalmologist may repeat the visual field test, obtain additional retinal imaging, compare prior scans, and communicate with the prescribing clinician before recommending any medication change.

Should hydroxychloroquine be stopped before an eye test?

No, it should not be stopped unless the prescribing clinician advises it. The screening tests are designed to assess the retina while treatment is ongoing, and stopping the medicine abruptly may worsen the condition being treated.

References

• American Academy of Ophthalmology
• Royal College of Ophthalmologists
• American College of Rheumatology
• National Eye Institute

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.